Researchers at MD Anderson Cancer Center find that FLAG-based combination therapy delivers strong long-term outcomes for core-binding factor acute myeloid leukemia patients.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
FLAG-based regimen delivers strong outcomes in subtype of acute myeloid leukemia
Fludarabine, Cytarabine, G-CSF Plus GO Or IDA Therapy components
Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Cancer subtype treated
University Of Texas MD Anderson Cancer Center Research institution